Last reviewed · How we verify
Angiotensin receptor blockers
At a glance
| Generic name | Angiotensin receptor blockers |
|---|---|
| Also known as | benidipine, angiotensin receptor blockers, Candesartan, Eprosartan, Irbesartan, Losartan |
| Sponsor | Seiji Umemoto, M.D., Ph.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (PHASE2)
- Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) (PHASE1, PHASE2)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angiotensin receptor blockers CI brief — competitive landscape report
- Angiotensin receptor blockers updates RSS · CI watch RSS
- Seiji Umemoto, M.D., Ph.D. portfolio CI